肝性脑病的预防与治疗进展

doi:10.3969/j.issn.1672-5069.2014.02.003

实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (2): 121-124.doi: 10.3969/j.issn.1672-5069.2014.02.003

肝性脑病的预防与治疗进展

张绪清

410038 重庆市第三军医大学西南医院全军感染病研究所

收稿日期:2013-12-05 修回日期:2016-04-15 出版日期:2014-08-20 发布日期:2016-04-15
作者简介:张绪清，男，48岁，医学博士，教授，主任医师，博士生导师。主要研究方向：乙型肝炎的免疫发病机制及肝衰竭的临床分期分型与治疗。E-mail: xuqing651005@tom.com

Advances in prevention and treatment of hepatic encephalopathy

Zhang Xuqing.

Institute of Infectious Diseases of PLA, Northwest Hospital,Third Military Medical University，Chongqing 410038,China. E-mail: xuqing651005@tom.com

Received:2013-12-05 Revised:2016-04-15 Online:2014-08-20 Published:2016-04-15

摘要/Abstract

关键词: 肝性脑病, 临床分型, “氨中毒”假说, 预防与治疗

Key words: Hepatic encephalopathy, Clinical classification, Ammonia poisoning, Hypothesis, Prevention and treatment

张绪清. 肝性脑病的预防与治疗进展[J]. 实用肝脏病杂志, 2014, 17(2): 121-124.

Zhang Xuqing.. Advances in prevention and treatment of hepatic encephalopathy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(2): 121-124.

[1] Beibel W，Al-Osaimi AM. Hepatic encephalopathy. Saudi J Gastroenterol，2012，18:301-309.
[2] Holeeek M. Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives. Metab Brain Dis，2013，DOI 10.1007/s11011-013-9428-9.
[3] Tranah TH，Vijay GK，Ryan JM，et al. Systemic inflammation and ammonia in hepatic encephalopathy. Metab Brain Dis，2013，28:1-5.
[4] Reddy PV，Rama Rao KV，Norenberg MD. Inhibitors of the mitochondrial permeability transition reduce ammonia-induced cell swelling in cultured astrocytes. J Neurosci Res，2009，87:2677-2685.
[5] Cordoba J，Minguez B. Hepatic encephalopathy. Semin Liver Dis，2008，28:70-80.
[6] Amodio P，Bemeur C，Butterworth R，et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology，2013，58:325-336.
[7] de Melo RT，Charneski L，Hilas O. Rifaximin for the treatment of hepatic encephalopathy. Am J Health Syst Pharm，2008，65:818-822.
[8] Chacko KR，Sigal SH. Update on management of patients with overt hepatic encephalopathy. Hosp Pract，2013，41:48-59.
[9] Alvares-da-Silva1 MR，de Araujo A，Vicenzi1 JR，et al. Oral L-ornithine-L-aspartate in minimal hepatic encephalopathy:a randomized，double blind placebo-controlled trial. Hepatol Res，2013， doi:10.1111/ hepr.12235.
[10] Jiang Q，Jiang G，Welty TE，et al. Naloxone in the management of hepatic encephalopathy. J Clin Pharm Ther，2010，35:333-341.
[11] Jiang Q，Jiang G，Shi KQ，et al. Oral acetyl-L-carnitine treatment in hepatic encephalopathy:view of evidence-based medicine. Ann Hepatol，2013，12:803-809.
[12] Bajaj JS，Pinkerton SD，Sanyal AJ，et al. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents:a cost-effectiveness analysis. Hepatology，2012，55（4）:1164-1171.
[13] Dhiman RK，Saraswat VA，Sharma BK，et al. Minimal hepatic encephalopathy:consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol，2010，25（6）:1029-1041.
[14] Ampuero J，Ranchal I，Nu ez D，et al. Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS One，2012，7（11）:e49279.
[15] Bajaj JS，Hafeezullah M，Franco J，et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology，2008，135（5）:1591-1600.
[16] Stephens S，Nyman H，Shane-McWhorter L. Assessing and treating hepatic encephalopathy in the older patient. Consult Pharm，2012，27（11）:797-802.
[17] Toris GT，Bikis CN，Tsourouflis GS，et al. Hepatic encephalopathy:an updated approach from pathogenesis to treatment. Med Sci Monit，2011，17（2）:RA53-63.
[18] Cudalbu C. In vivo studies of brain metabolism in animal models of hepatic encephalopathy using H magnetic resonance spectroscopy. Metab Brain Dis，2013，28（2）:167-174.
[19] Prakash RK，Kanna S，Mullen KD. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis. Clin Ther，2013，35（9）:1458-1473.
[20] Prakash R，Mullen KD. Mechanisms，diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol，2010，7（9）:515-525.
[21] Zhan T，Stremmel W. The diagnosis and treatment of minimal hepatic encephalopathy. Dtsch Arztebl Int，2012，109（10）:180-187.
[22] Montgomery JY，Bajaj JS. Advances in the evaluation and management of minimal hepatic encephalopathy. Curr Gastroenterol Rep，2011，13（1）:26-33.

肝性脑病的预防与治疗进展

Advances in prevention and treatment of hepatic encephalopathy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[2]	任宏伟, 高志华. 静息态fMRI技术观察肝性脑病患者双侧苍白球与全脑网络连接的改变研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 920-923.
[3]	王军, 张流, 熊华刚, 杨智刚, 王梅, 李勇富. 醒脑静联合纳洛酮治疗肝性脑病患者认知和血清炎症因子水平变化*[J]. 实用肝脏病杂志, 2018, 21(3): 471-472.
[4]	孙晓. 微生态制剂联合肠内营养治疗肝性脑病患者营养学及血清指标的变化[J]. 实用肝脏病杂志, 2017, 20(6): 777-778.
[5]	花兴萍, 朱蔚岗, 刘明水. 细菌感染诱发乙型肝炎肝硬化患者发生肝性脑病60例回顾性研究[J]. 实用肝脏病杂志, 2017, 20(3): 358-359.
[6]	陈振道, 陈浩. 脑活素联合微生态制剂治疗肝性脑病患者疗效观察^*[J]. 实用肝脏病杂志, 2016, 19(5): 583-586.
[7]	陈东风, 孙文静. 肝性脑病的新认识-从指南到临床[J]. 实用肝脏病杂志, 2016, 19(1): 16-19.
[8]	郝艳爽, 马普红, 曹建国, 邓玉花, 索成云. 乙型肝炎肝衰竭患者并发肝性脑病危险因素分析[J]. 实用肝脏病杂志, 2016, 19(1): 90-91.
[9]	陈广建，谢碧梅，李祥兴，刘洁. 肝硬化并发肝性脑病的诱因和预后分析[J]. 实用肝脏病杂志, 2015, 18(5): 548-549.
[10]	张敏. 失代偿期肝硬化患者发生肝性脑病的危险因素分析[J]. 实用肝脏病杂志, 2015, 18(2): 188-190.
[11]	宋秀丽. 左旋门冬氨酸鸟氨酸联合纳洛酮治疗肝性脑病患者疗效观察[J]. 实用肝脏病杂志, 2015, 18(1): 82-83.
[12]	陈宇宁, 王锦辉, 薛立峰, 林述洲, 林耿鹏, 陈旻湖. 不同临床分型的Wilson’s病临床特点分析[J]. 实用肝脏病杂志, 2014, 17(4): 392-396.
[13]	何润莲综述, 杨晋辉审校. 轻微型肝性脑病诊断研究进展[J]. 实用肝脏病杂志, 2014, 17(3): 325-329.
[14]	孙文锦, 王立志, 王运东, 汪燕. 门冬氨酸鸟氨酸联合乳果糖灌肠治疗肝性脑病疗效观察[J]. 实用肝脏病杂志, 2014, 17(1): 86-87.
[15]	李晶莹,顾锡炳. 门冬氨酸鸟氨酸治疗肝性脑病的临床研究[J]. 实用肝脏病杂志, 2011, 14(4): 298-298.